An Interview from the 2015 American Society of Hematology Annual Meeting with Dr. Richard Furman on the Emerging Role of Novel Agents in CLL By Brian Koffman, MD and Richard Furman, MD The data is maturing and the therapies just keep getting better. Dr.... September 19, 20172015 ConferencesBy clladm1n
ASH 2015: Dr. Wiestner on B Cell Receptors and Toll-Like Receptors in CLL Dr. Adrian Wiestner of the NIH not only does important clinical trials but also does important bench science on what... November 14, 20162015 ConferencesBy Todd Dennison
ASH 2015: Dr. Wiestner on Clonal Evolution in CLL Patients on Ibrutinib In the first of a two part interview from ASH 2015, Dr. Adrian Wiestner of the NIH discussed clonal evolution... October 17, 20162015 ConferencesBy Todd Dennison
ASH 2015: Dr. Castro on HDMP and Obinutuzumab for CLL Dr. Januario Castro and the other doctors at the University of California, San Diego Moores Cancer Center have pushed for... August 30, 20162015 ConferencesBy Todd Dennison
ASH 2015: Dr. Jeff Jones on Venetoclax Used after Stopping a B-Cell Receptor in CLL Dr. Jeff Jones out of Ohio State University tells us in this interview from ASH 2015 that there is hope... August 23, 20162015 ConferencesBy Todd Dennison
ASH 2015: Dr. Rick Furman Discusses the New Prognostic Factors and MRD Negativity in CLL There has been an explosion of understanding about prognostic markers for chronic lymphocytic leukemia (CLL), with the increased ability to... July 18, 20162015 ConferencesBy Todd Dennison
2015 ASH: Dr. John Byrd Discusses ACP 196 or Acalabrutinib, a new BTK inhibitor In this video interview with Dr. John Byrd, my treating physician at the Ohio State University, I caught up with... June 9, 20162015 ConferencesBy clladm1n
Dr. Kipps on Signal Blockers, Venetoclax, ROR1 Antibodies and the Importance of More Research Thomas Kipps, MD, PhD, Deputy Director of Research Operations at the Moores Cancer Center at UCSD is not only a... June 6, 20162015 ConferencesBy Todd Dennison
ASH 2015: What Happens when CLL Patients Stop Ibrutinib or Idelalisib Dr. Anthony Mato of the University of Pennsylvania asked questions about what happened when patient stopped their oral kinase inhibitors... May 31, 20162015 ConferencesBy Todd Dennison
ASH 2015: Study to Improve Fatigue in CLL Patients Who Do Not Currently Require Active Treatment Many patients with chronic lymphocytic leukemia (CLL) experience significant fatigue and other symptoms that negatively impact their quality of life.... April 4, 20162015 ConferencesBy Todd Dennison
